Skip to main content
Erschienen in: European Archives of Psychiatry and Clinical Neuroscience 2/2016

01.03.2016 | Original Paper

The public debate on psychotropic medication and changes in attitudes 1990–2011

verfasst von: Matthias C. Angermeyer, Sandra Van der Auwera, Herbert Matschinger, Mauro G. Carta, Sebastian E. Baumeister, Georg Schomerus

Erschienen in: European Archives of Psychiatry and Clinical Neuroscience | Ausgabe 2/2016

Einloggen, um Zugang zu erhalten

Abstract

Over the last 25 years, the appraisal of psychotropic drugs within the scientific community and their representation in the media has changed considerably. The initial optimism in the wake of the introduction of second-generation drugs has increasingly made room for a more critical evaluation of alleged advantages of these drugs. The question arises as to what extent this is reflected in similar changes in the public’s attitudes towards psychiatric medication. Three representative population surveys on attitudes towards psychotropic medication were carried out in Germany in 1990 (N = 3075), 2001 (N = 2610) and 2011 (N = 1223), using the same sampling procedure, interview mode and instrument for assessing attitudes. In order to disentangle time-related effects, an age–period–cohort analysis was performed. Over the time period of 21 years, the German public’s evaluation of psychotropic medication has become markedly more favourable. This change was mostly due to a period effect, i.e. concurrent influences of the social environment people are exposed to. Changes were much more pronounced in the 1990s, while over the following decade only a small, although statistically significant, increase in the favourable appraisal of medication was found. Age and birth cohort had only a minor effect on public attitudes. Our findings suggest that changes in the evaluation of the effects of psychotropic drugs within the psychiatric community and their representation in the media also affect public opinion. Given the ongoing debate about side effects and efficacy of psychiatric medication, future changes of public opinion can be expected.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Schumer F (1989) Bye–bye blues: a new wonder drug for depression. New Yorker 18(22):46–50 Schumer F (1989) Bye–bye blues: a new wonder drug for depression. New Yorker 18(22):46–50
2.
Zurück zum Zitat Montagne M (2001) Mass media representations as drug information for patients: the Prozac phenomenon. Subst Use Misuse 36:1261–1274CrossRefPubMed Montagne M (2001) Mass media representations as drug information for patients: the Prozac phenomenon. Subst Use Misuse 36:1261–1274CrossRefPubMed
3.
Zurück zum Zitat Toufexis A (1993) Personality pill, Prozac. TIME 11:62–63 Toufexis A (1993) Personality pill, Prozac. TIME 11:62–63
4.
Zurück zum Zitat Walberg (1990) Promise of Prozac. Newsweek 57:26–38 Walberg (1990) Promise of Prozac. Newsweek 57:26–38
5.
Zurück zum Zitat Kramer PD (1993) Listening to Prozac. Penguin Books, New York Kramer PD (1993) Listening to Prozac. Penguin Books, New York
6.
Zurück zum Zitat Wurtzel E (1994) Prozac nation. Houghton Mifflin, Boston Wurtzel E (1994) Prozac nation. Houghton Mifflin, Boston
7.
Zurück zum Zitat Elfenbein D (ed) (1995) Living with Prozac and other selective serotonin-reuptake inhibitors. HarperCollins, New York Elfenbein D (ed) (1995) Living with Prozac and other selective serotonin-reuptake inhibitors. HarperCollins, New York
8.
Zurück zum Zitat Rosenheck R, Perlick D, Bingham S, Liu-Mares W, Collins J, Warren S, Leslie D, Allan E, Cambell EC, Caroff S, Corwin J, Davis L, Douyon R, Dunn L, Evans D, Frecska E, Grabowski J, Graeber D, Herz L, Kwon K, Lawson W, Mena F, Sheikh J, Smelson D, Smith-Gamble V (2003) Effectiveness and cost of olanzapine and haloperidol in the treatment of schizophrenia: a randomized controlled trial. JAMA 290:2693–2702CrossRefPubMed Rosenheck R, Perlick D, Bingham S, Liu-Mares W, Collins J, Warren S, Leslie D, Allan E, Cambell EC, Caroff S, Corwin J, Davis L, Douyon R, Dunn L, Evans D, Frecska E, Grabowski J, Graeber D, Herz L, Kwon K, Lawson W, Mena F, Sheikh J, Smelson D, Smith-Gamble V (2003) Effectiveness and cost of olanzapine and haloperidol in the treatment of schizophrenia: a randomized controlled trial. JAMA 290:2693–2702CrossRefPubMed
9.
Zurück zum Zitat Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DA, Keefe RSE, Davis SM, Davis CE, Lebowitz BD, Severe J, Hsiao JK (2005) Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 353:1209–1223CrossRefPubMed Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DA, Keefe RSE, Davis SM, Davis CE, Lebowitz BD, Severe J, Hsiao JK (2005) Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 353:1209–1223CrossRefPubMed
10.
Zurück zum Zitat Jones PB, Barnes TRE, Davies L, Dunn G, Lloyd H, Hayhurst KP, Murray RM, Markwick QA, Lewis SW (2006) Randomized controlled trial of the effect on quality of life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1). Arch Gen Psychiatry 63:1079–1086CrossRefPubMed Jones PB, Barnes TRE, Davies L, Dunn G, Lloyd H, Hayhurst KP, Murray RM, Markwick QA, Lewis SW (2006) Randomized controlled trial of the effect on quality of life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1). Arch Gen Psychiatry 63:1079–1086CrossRefPubMed
11.
Zurück zum Zitat Kahn RS, Fleischhacker WW, Boter H, Davidson M, Vergouwe Y, Keet IPM, Gheorge MD, Rybakowski JK, Galderisi S, Libiger J, Hummer M, Dollfus S, Lopez-Ibor JJ, Hranov LG, Gaebel W, Peuskens J, Lindefons N, Riecher-Rössler A, Grobee DE (2008) Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomized clinical trial. Lancet 371:1085–1097CrossRefPubMed Kahn RS, Fleischhacker WW, Boter H, Davidson M, Vergouwe Y, Keet IPM, Gheorge MD, Rybakowski JK, Galderisi S, Libiger J, Hummer M, Dollfus S, Lopez-Ibor JJ, Hranov LG, Gaebel W, Peuskens J, Lindefons N, Riecher-Rössler A, Grobee DE (2008) Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomized clinical trial. Lancet 371:1085–1097CrossRefPubMed
12.
Zurück zum Zitat Lewis S (2009) Second-generation antipsychotics: a therapeutic downturn? Psychol Med 39:1603–1606CrossRefPubMed Lewis S (2009) Second-generation antipsychotics: a therapeutic downturn? Psychol Med 39:1603–1606CrossRefPubMed
13.
Zurück zum Zitat Leucht S, Kissling W, Davis JM (2009) Second-generation antipsychotics for schizophrenia: can we resolve the conflict? Psychol Med 39:1591–1602CrossRefPubMed Leucht S, Kissling W, Davis JM (2009) Second-generation antipsychotics for schizophrenia: can we resolve the conflict? Psychol Med 39:1591–1602CrossRefPubMed
14.
Zurück zum Zitat Kirsch I, Deacon BJ, Huedo-Medina TB, Scoboria A, Moore TJ, Johnson BT (2008) Initial severity and antidepressant benefits: a meta-analysis of data submitted to the Food and Drug Administration. PLoS Med 5:ee45CrossRef Kirsch I, Deacon BJ, Huedo-Medina TB, Scoboria A, Moore TJ, Johnson BT (2008) Initial severity and antidepressant benefits: a meta-analysis of data submitted to the Food and Drug Administration. PLoS Med 5:ee45CrossRef
15.
Zurück zum Zitat Horder J, Matthews P, Waldmann R (2011) Placebo, Prozac and PLoS: significant lessons for psychopharmacology. J Psychopharmacol 25:1277–1288CrossRefPubMed Horder J, Matthews P, Waldmann R (2011) Placebo, Prozac and PLoS: significant lessons for psychopharmacology. J Psychopharmacol 25:1277–1288CrossRefPubMed
16.
Zurück zum Zitat Möller HJ (2008) Isn’t the efficacy of antidepressants clinically relevant? A critical comment on the results of the meta-analysis by Kirsch et al. 2008. Eur Arch Psychiatry Clin Neurosci 258:451–455CrossRefPubMed Möller HJ (2008) Isn’t the efficacy of antidepressants clinically relevant? A critical comment on the results of the meta-analysis by Kirsch et al. 2008. Eur Arch Psychiatry Clin Neurosci 258:451–455CrossRefPubMed
17.
Zurück zum Zitat Fountoulakis KN, Möller HJ (2011) Efficacy of antidepressants: a re-analysis and re-interpretation of the Kirsch data. Int J Neuropsychopharmacol 14:405–412CrossRefPubMed Fountoulakis KN, Möller HJ (2011) Efficacy of antidepressants: a re-analysis and re-interpretation of the Kirsch data. Int J Neuropsychopharmacol 14:405–412CrossRefPubMed
18.
Zurück zum Zitat Huedo-Medina TB, Johnson BT, Kirsch I (2012) Kirsch et al’.s (2008) calculations are correct: reconsidering Fountoulakis & Möller’s re-analysis of the Kirsch data. Int J Neuropsychopharmacol 15:1193–1198CrossRefPubMed Huedo-Medina TB, Johnson BT, Kirsch I (2012) Kirsch et al’.s (2008) calculations are correct: reconsidering Fountoulakis & Möller’s re-analysis of the Kirsch data. Int J Neuropsychopharmacol 15:1193–1198CrossRefPubMed
19.
Zurück zum Zitat Shafy S (2008) Entzauberte Glückspillen [Happiness pills deprived of its mystique]. DER SPIEGEL 10:172–174 Shafy S (2008) Entzauberte Glückspillen [Happiness pills deprived of its mystique]. DER SPIEGEL 10:172–174
20.
Zurück zum Zitat Bartens W (2008) Gegen Traurigkeit hilft keine Pille. Weitverbreitete Antidepressiva zeigen kaum Wirkung [Pills do not help against sadness—commonly used antidepressants hardly show any effect]. Süddeutsche Zeitung February 02 Bartens W (2008) Gegen Traurigkeit hilft keine Pille. Weitverbreitete Antidepressiva zeigen kaum Wirkung [Pills do not help against sadness—commonly used antidepressants hardly show any effect]. Süddeutsche Zeitung February 02
21.
Zurück zum Zitat Schomerus G, Van der Auwera S, Matschinger H, Baumeister SE, Angermeyer MC (2015) Do attitudes towards persons with mental illness worsen during the course of life? An age–period–cohort analysis. Acta Psychiatr Scand. doi:10.1111/acps.12401 PubMed Schomerus G, Van der Auwera S, Matschinger H, Baumeister SE, Angermeyer MC (2015) Do attitudes towards persons with mental illness worsen during the course of life? An age–period–cohort analysis. Acta Psychiatr Scand. doi:10.​1111/​acps.​12401 PubMed
22.
Zurück zum Zitat Farrer L, Leach L, Griffiths KM, Christensen H, Jorm AF (2008) Age differences in mental health literacy. BMC Publ Health 8:125CrossRef Farrer L, Leach L, Griffiths KM, Christensen H, Jorm AF (2008) Age differences in mental health literacy. BMC Publ Health 8:125CrossRef
23.
Zurück zum Zitat Angermeyer MC, Däumer R, Matschinger H (1993) Benefits and risks of psychotropic medication in the eyes of the general public: results of a survey in the Federal Republic of Germany. Pharmacopsychiatry 26:114–120CrossRefPubMed Angermeyer MC, Däumer R, Matschinger H (1993) Benefits and risks of psychotropic medication in the eyes of the general public: results of a survey in the Federal Republic of Germany. Pharmacopsychiatry 26:114–120CrossRefPubMed
24.
Zurück zum Zitat Angermeyer MC, Matschinger H (2004) Public attitudes towards psychotropic drugs: have there been any changes within recent years? Pharmacopsychiatry 37:152–156CrossRefPubMed Angermeyer MC, Matschinger H (2004) Public attitudes towards psychotropic drugs: have there been any changes within recent years? Pharmacopsychiatry 37:152–156CrossRefPubMed
25.
Zurück zum Zitat Harrell FE Jr (2001) Regression modeling strategies. With applications to linear models, logistic regression, and survival analysis. Springer, New York Harrell FE Jr (2001) Regression modeling strategies. With applications to linear models, logistic regression, and survival analysis. Springer, New York
26.
Zurück zum Zitat Mirnezami HF, Jacobsson L, Edin-Liljegren A (2015) Changes in attitudes towards mental disorders and psychiatric treatment 1976–2014 in a Swedish population. Nord J Psychiatry. doi:10.3109/08039488.2015.1046916 Mirnezami HF, Jacobsson L, Edin-Liljegren A (2015) Changes in attitudes towards mental disorders and psychiatric treatment 1976–2014 in a Swedish population. Nord J Psychiatry. doi:10.​3109/​08039488.​2015.​1046916
27.
Zurück zum Zitat Reavley NJ, Jorm AF (2012) Belief in the harmfulness of antidepressants: associated factors and change over 16-years. J Affect Disord 138:375–386CrossRefPubMed Reavley NJ, Jorm AF (2012) Belief in the harmfulness of antidepressants: associated factors and change over 16-years. J Affect Disord 138:375–386CrossRefPubMed
28.
Zurück zum Zitat Reavley NJ, Cvetkovski S, Jorm AF (2013) The Australian public’s belief about the harmfulness of antipsychotics: associated factors and change over 16-years. Psychiatry Res 206:307–312CrossRefPubMed Reavley NJ, Cvetkovski S, Jorm AF (2013) The Australian public’s belief about the harmfulness of antipsychotics: associated factors and change over 16-years. Psychiatry Res 206:307–312CrossRefPubMed
29.
Zurück zum Zitat Lauber C, Falcato L, Nordt C, Rössler W (2003) Lay beliefs about causes of depression. Acta Psychiatr Scand 108(Suppl. 418):96–99CrossRef Lauber C, Falcato L, Nordt C, Rössler W (2003) Lay beliefs about causes of depression. Acta Psychiatr Scand 108(Suppl. 418):96–99CrossRef
30.
Zurück zum Zitat Riedel-Heller SG, Matschinger H, Angermeyer MC (2005) Mental disorders—who and what might help. Soc Psychiatry Psychiatr Epidemiol 40:167–174CrossRefPubMed Riedel-Heller SG, Matschinger H, Angermeyer MC (2005) Mental disorders—who and what might help. Soc Psychiatry Psychiatr Epidemiol 40:167–174CrossRefPubMed
31.
Zurück zum Zitat Carta MG, Angermeyer MC, Matschinger H, Holzinger A, Pintus E, Pintus M, Moro MF (2014) Recommendations of the Sardinian public for the treatment of depression. Int J Soc Psychiatry 60:619–626CrossRefPubMed Carta MG, Angermeyer MC, Matschinger H, Holzinger A, Pintus E, Pintus M, Moro MF (2014) Recommendations of the Sardinian public for the treatment of depression. Int J Soc Psychiatry 60:619–626CrossRefPubMed
32.
Zurück zum Zitat Partridge B, Lucke J, Hall W (2012) Public attitudes towards the acceptability of using drugs to treat depression and ADHD. Aust N Z J Psychiatry 46:958–965CrossRefPubMed Partridge B, Lucke J, Hall W (2012) Public attitudes towards the acceptability of using drugs to treat depression and ADHD. Aust N Z J Psychiatry 46:958–965CrossRefPubMed
33.
Zurück zum Zitat Goetz J, Fuchs C (2013) Die Pille zum Glück. Wie die Pharmaindustrie trickste, um die Zulassung für gefährliche Antidepressiva zu erhalten [The Happiness Pill. How pharmaceutical companies managed to get approval for dangerous antidepressants]. Süddeutsche Zeitung February 16/17 Goetz J, Fuchs C (2013) Die Pille zum Glück. Wie die Pharmaindustrie trickste, um die Zulassung für gefährliche Antidepressiva zu erhalten [The Happiness Pill. How pharmaceutical companies managed to get approval for dangerous antidepressants]. Süddeutsche Zeitung February 16/17
34.
Zurück zum Zitat Le Noury J, Nardo JM, Healey D, Jureidini J, Raven M, Tufanaru C, Abi-Jaoude E (2015) Restoring Study 329: efficacy and harms of paroxetine and imipramine in treatment of major depression in adolescence. BMJ 351:h4320PubMedCentralCrossRefPubMed Le Noury J, Nardo JM, Healey D, Jureidini J, Raven M, Tufanaru C, Abi-Jaoude E (2015) Restoring Study 329: efficacy and harms of paroxetine and imipramine in treatment of major depression in adolescence. BMJ 351:h4320PubMedCentralCrossRefPubMed
35.
Zurück zum Zitat Harrow M, Jobe TH, Faull RN (2014) Does treatment of schizophrenia with antipsychotic medications eliminate or reduce psychosis? A 20-year multi-follow-up study. Psychol Med 44:3007–3016CrossRefPubMed Harrow M, Jobe TH, Faull RN (2014) Does treatment of schizophrenia with antipsychotic medications eliminate or reduce psychosis? A 20-year multi-follow-up study. Psychol Med 44:3007–3016CrossRefPubMed
36.
Zurück zum Zitat Bartens W (2015) Medikamentenstudie vom Ghostwriter [Ghostwriters’ drug study]. Süddeutsche Zeitung 17.09 Bartens W (2015) Medikamentenstudie vom Ghostwriter [Ghostwriters’ drug study]. Süddeutsche Zeitung 17.09
37.
Zurück zum Zitat Lenzen-Schulte M (2015) Wenn Psychopillen das Gehirn schrumpfen lassen [When psycho pills let the brain shrink]. Frankfurter Allgemeine Zeitung 26.01.15 Lenzen-Schulte M (2015) Wenn Psychopillen das Gehirn schrumpfen lassen [When psycho pills let the brain shrink]. Frankfurter Allgemeine Zeitung 26.01.15
Metadaten
Titel
The public debate on psychotropic medication and changes in attitudes 1990–2011
verfasst von
Matthias C. Angermeyer
Sandra Van der Auwera
Herbert Matschinger
Mauro G. Carta
Sebastian E. Baumeister
Georg Schomerus
Publikationsdatum
01.03.2016
Verlag
Springer Berlin Heidelberg
Erschienen in
European Archives of Psychiatry and Clinical Neuroscience / Ausgabe 2/2016
Print ISSN: 0940-1334
Elektronische ISSN: 1433-8491
DOI
https://doi.org/10.1007/s00406-015-0660-7

Weitere Artikel der Ausgabe 2/2016

European Archives of Psychiatry and Clinical Neuroscience 2/2016 Zur Ausgabe

Update Psychiatrie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.